HopeStage
Back to all studies
CompletedNCT01795183

Amisulpride Safety and Outcomes in Chinese Patients With Schizophrenia

About this titleRead the official source — NCT01795183

Researchers studied AMISULPRIDE to find out how it affected psychotic symptoms in people with schizophrenia.

Medication studyAges 18–65China
The study in practice

Understand this study

What did researchers investigate?

Researchers studied AMISULPRIDE to find out how it affected psychotic symptoms in people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
BeijingSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2012
Recruitment status
Completed
Enrollment listed in the registry
316
Sponsor
Sanofi
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
China
Age range
From 18 Years to 65 Years
Official registry ID
NCT01795183
Official title
Show the full official title

The Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia - A Prospective Open-Label Multicenter Study

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Beijing

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers studied AMISULPRIDE to find out how it affected psychotic symptoms in people with schizophrenia.

Who is behind this study?

The study sponsor is Sanofi.

Did this study involve medication?

Yes. The study involved medication, including AMISULPRIDE.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies